SCHEMBL3318035

SCHEMBL3318035

NC1CN(C(=O)Cc2ccc(Oc3ccccc3)cc2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.53
ALDH1A1 P00352 3/20 0.50
HPGD P15428 1/20 0.50
LMNA P02545 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TSHR P16473 1/20 0.49
USP2 O75604 1/20 0.49
GAA P10253 1/20 0.49
SRD5A2 P31213 2/20 0.49
CHRNB2 P17787 1/20 0.46
CHRNB4 P30926 1/20 0.46
CHRNA3 P32297 1/20 0.46
CHRNA7 P36544 1/20 0.46
CHRNA4 P43681 1/20 0.46
FFAR1 O14842 1/20 0.45
TPSAB1 Q15661 1/20 0.45
TPSD1 Q9BZJ3 1/20 0.45
TPSG1 Q9NRR2 1/20 0.45
MMP2 P08253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3313789 0.78 FAAH (0.46) FAAHALDH1A1HPGDLMNARAB9A
SCHEMBL3317869 0.77 HRH3 (0.47) FAAHALDH1A1HPGDLMNARAB9A
SCHEMBL17304821 0.77 ALDH1A1 (0.72) ALDH1A1HPGDLMNARAB9ASMN1; SMN2
SCHEMBL3316432 0.76 KMT2A (0.47) FAAHALDH1A1HPGDLMNARAB9A
SCHEMBL16002988 0.75 EPHX2 (0.56) FAAHALDH1A1LMNARAB9ASMN1; SMN2
SCHEMBL27713178 0.75 ALDH1A1 (0.67) ALDH1A1LMNARAB9ATSHRUSP2
SCHEMBL16000498 0.73 ALDH1A1 (0.54) FAAHALDH1A1LMNARAB9ASMN1; SMN2
SCHEMBL2734987 0.73 SRD5A2 (0.62) SMN1; SMN2SRD5A2FFAR1NR3C1LTA4H
SCHEMBL12207405 0.72 ALDH1A1 (0.63) ALDH1A1HPGDLMNARAB9ASMN1; SMN2
SCHEMBL1145770 0.72 SRD5A2 (0.83) LMNATSHRGAASRD5A2FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105651-A1 ANTAGONISTS OF SNS SODIUM CHANNELS VERNALIS (R&D) LIMITED (GB) 2010-04-29 US disclosed
EP-1933830-A1 ANTAGONISTS OF SNS SODIUM CHANNELS Vernalis (R&D) Limited (GB) 2008-06-25 EP disclosed
WO-2007007057-A1 ANTAGONISTS OF SNS SODIUM CHANNELS VERNALIS (R & D) LIMITED (GB) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105651-A1 ANTAGONISTS OF SNS SODIUM CHANNELS CNR1, OPRL1, CHRNA10 FAAH 637/4885ALDH1A1 1255/4885HPGD 1482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.